Argenx advances FB102 to Phase 3 after celiac win, but Vyvgart Sjögren’s failure hits stock
Argenx reported that its anti-CD122 antibody FB102 met its primary endpoint in a Phase 2 celiac disease trial, supporting a move to Phase 3. Simultaneously, the company announced that its blockbuster drug Vyvgart failed a Phase 3 trial for Sjögren’s disease, causing shares to drop 13%.